Literature DB >> 26393335

Severe placental abruption: clinical definition and associations with maternal complications.

Cande V Ananth1, Jessica A Lavery2, Anthony M Vintzileos3, Daniel W Skupski4, Michael Varner5, George Saade6, Joseph Biggio7, Michelle A Williams8, Ronald J Wapner9, Jason D Wright9.   

Abstract

BACKGROUND: Placental abruption traditionally is defined as the premature separation of the implanted placenta before the delivery of the fetus. The existing clinical criteria of severity rely exclusively on fetal (fetal distress or fetal death) and maternal complications without consideration of neonatal or preterm delivery-related complications. However, two-thirds of abruption cases are accompanied by fetal or neonatal complications, including preterm delivery. A clinically meaningful classification for abruption therefore should include not only maternal complications but also adverse fetal and neonatal outcomes that include intrauterine growth restriction and preterm delivery.
OBJECTIVES: The purpose of this study was to define severe placental abruption and to compare serious maternal morbidity profiles of such cases with all other cases of abruption (ie, mild abruption) and nonabruption cases. STUDY
DESIGN: We performed a retrospective cohort analysis using the Premier database of hospitalizations that resulted in singleton births in the United States between 2006 and 2012 (n = 27,796,465). Severe abruption was defined as abruption accompanied by at least 1 of the following events: maternal (disseminated intravascular coagulation, hypovolemic shock, blood transfusion, hysterectomy, renal failure, or in-hospital death), fetal (nonreassuring fetal status, intrauterine growth restriction, or fetal death), or neonatal (neonatal death, preterm delivery or small for gestational age) complications. Abruption cases that did not qualify as being severe were classified as mild abruption cases. The morbidity profile included amniotic fluid embolism, pulmonary edema, acute respiratory or heart failure, acute myocardial infarction, cardiomyopathy, puerperal cerebrovascular disorders, or coma. Associations were expressed as rate ratios with 95% confidence intervals that were derived from fitting log-linear Poisson regression models.
RESULTS: The overall prevalence rate of abruption was 9.6 per 1000, of which two-thirds of cases were classified as being severe (6.5 per 1000). Serious maternal complications occurred in 15.4, 33.3, and 141.7 per 10,000 among nonabruption cases and mild and severe abruption cases, respectively. In comparison with no abruption, the rate ratio for serious maternal complications were 1.52 (95% confidence interval, 1.35-1.72) and 4.29 (95% confidence interval, 4.11-4.47) in women with mild and severe placental abruption, respectively. Rate ratios for the individual complications were 2- to 7-fold higher among severe abruption cases. Furthermore, the rate ratios for serious maternal complications among severe abruption cases compared with mild abruption cases was 3.47 (95% confidence interval, 3.05-3.95). This association was considerably stronger for virtually all maternal complications among cases with severe abruption compared with mild abruption. Annual rates of mild and severe abruption were fairly constant during the study period. Although the maternal complication rate among non-abruption births was stable from 2006-2012, the rate of complications among mild abruption cases dropped from 2006-2008 and then leveled off thereafter. In contrast, the rate of serious complications among severe abruption cases remained fairly stable from 2006-2010 and increased sharply thereafter.
CONCLUSIONS: Severe abruption was associated with a distinctively higher morbidity risk profile compared with the other 2 groups. The clinical characteristics and morbidity profile of mild abruption were more similar to those of women without an abruption. These findings suggest that the definition of severe placental abruption based on the proposed specific criteria is clinically relevant and may facilitate epidemiologic and genetic research.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  blood transfusion; disseminated intravascular coagulation; fetal death; intrauterine growth restriction; maternal complication; placental abruption; preterm delivery

Mesh:

Year:  2015        PMID: 26393335     DOI: 10.1016/j.ajog.2015.09.069

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  Genetic variations and risk of placental abruption: A genome-wide association study and meta-analysis of genome-wide association studies.

Authors:  Tsegaselassie Workalemahu; Daniel A Enquobahrie; Bizu Gelaye; Sixto E Sanchez; Pedro J Garcia; Fasil Tekola-Ayele; Anjum Hajat; Timothy A Thornton; Cande V Ananth; Michelle A Williams
Journal:  Placenta       Date:  2018-04-16       Impact factor: 3.481

Review 2.  Maternal, Labor, Delivery, and Perinatal Outcomes Associated with Placental Abruption: A Systematic Review.

Authors:  Katheryne L Downes; Katherine L Grantz; Edmond D Shenassa
Journal:  Am J Perinatol       Date:  2017-03-22       Impact factor: 1.862

3.  Abruptio placentae risk and genetic variations in mitochondrial biogenesis and oxidative phosphorylation: replication of a candidate gene association study.

Authors:  Tsegaselassie Workalemahu; Daniel A Enquobahrie; Bizu Gelaye; Timothy A Thornton; Fasil Tekola-Ayele; Sixto E Sanchez; Pedro J Garcia; Henry G Palomino; Anjum Hajat; Roberto Romero; Cande V Ananth; Michelle A Williams
Journal:  Am J Obstet Gynecol       Date:  2018-09-05       Impact factor: 8.661

4.  The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Offer Erez; Adi L Tarca; Agustin Conde-Agudelo; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo; Steven J Korzeniewski
Journal:  Am J Obstet Gynecol       Date:  2017-10-13       Impact factor: 8.661

5.  First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption.

Authors:  Cande V Ananth; Ronald J Wapner; Srinidhi Ananth; Mary E DʼAlton; Anthony M Vintzileos
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

6.  Maternal-fetal genetic interactions, imprinting, and risk of placental abruption.

Authors:  Tsegaselassie Workalemahu; Daniel A Enquobahrie; Bizu Gelaye; Mahlet G Tadesse; Sixto E Sanchez; Fasil Tekola-Ayele; Anjum Hajat; Timothy A Thornton; Cande V Ananth; Michelle A Williams
Journal:  J Matern Fetal Neonatal Med       Date:  2020-09-24

7.  Fetal death: an extreme manifestation of maternal anti-fetal rejection.

Authors:  Kia Lannaman; Roberto Romero; Tinnakorn Chaiworapongsa; Yeon Mee Kim; Steven J Korzeniewski; Eli Maymon; Nardhy Gomez-Lopez; Bogdan Panaitescu; Sonia S Hassan; Lami Yeo; Bo Hyun Yoon; Chong Jai Kim; Offer Erez
Journal:  J Perinat Med       Date:  2017-10-26       Impact factor: 1.901

8.  Teenage pregnancy as a risk factor for placental abruption: Findings from the prospective Japan environment and children's study.

Authors:  Hyo Kyozuka; Tsuyoshi Murata; Toma Fukusda; Akiko Yamaguchi; Aya Kanno; Shun Yasuda; Akiko Sato; Yuka Ogata; Yuta Endo; Mitsuaki Hosoya; Seiji Yasumura; Koichi Hashimoto; Hidekazu Nishigori; Keiya Fujimori
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

9.  Mechanisms of death in structurally normal stillbirths.

Authors:  Percy Pacora; Roberto Romero; Sunil Jaiman; Offer Erez; Gaurav Bhatti; Bogdan Panaitescu; Neta Benshalom-Tirosh; Eun Jung Jung; Chaur-Dong Hsu; Sonia S Hassan; Lami Yeo; Nicholas Kadar
Journal:  J Perinat Med       Date:  2019-02-25       Impact factor: 2.716

10.  Risk Factors for Neonatal/Maternal Morbidity and Mortality in African American Women with Placental Abruption.

Authors:  Deena Elkafrawi; Giovanni Sisti; Sarah Araji; Aldo Khoury; Jacob Miller; Brian Rodriguez Echevarria
Journal:  Medicina (Kaunas)       Date:  2020-04-13       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.